Myocardial protective effects of the class Ic antiarrhythmic agent flecainide

L. A. Brunsting, Michael E Jessen, A. S. Ebd-Elfattah, W. K. Mask, C. K. Godwin, A. S. Wechsler

Research output: Contribution to journalArticle

Abstract

The class Ic antiarrhythmic agent flecainide has recently become available in this country for management of ventricular arrhythmias. The pharmacologic and electrophysiologic features of this class of drug - marked sodium channel blockade producing inhibition of phase 0 of the myocardial action potential, moderate blockade of slow inward (calcium) channels, and general lack of systemic toxicity - suggest that these agents may exert significant myocardial protective effects. This hypothesis was tested in isolated, perfused rat hearts subjected to 30 minutes of global normothermic ischemia followed by 30 minutes of reperfusion after pretreatment with (1) Krebs-Henseleit buffer (n = 7); (2) Krebs-Henseleit buffer with potassium adjusted to 20.9 mmol/L with potassium chloride (n = 10); and (3) Krebs-Henseleit buffer plus flecainide acetate 50 mg/L (0.12 mmol/L) (n = 11). Severity of ischemic injury was assessed by time to ischemic contracture: 9.9 ± 1.3 (Krebs-Henseleit buffer), 18.4 ± 1.1 (potassium chloride), and 25.4 ± 1.0 (flecainide) minutes (mean ± standard error of the mean) (p < 0.05 among all groups). Functional recovery after ischemia and reperfusion was measured by developed pressure (expressed as percent of preischemic control): 19.6 ± 5.4 (Krebs-Henseleit buffer), 70.8 ± 3.2 (potassium chloride), and 67.3 ± 2.7 (flecainide). These results suggest that class Ic agents afford significant myocardial protection from global normothermic ischemia.

Original languageEnglish (US)
Pages (from-to)904-910
Number of pages7
JournalJournal of Thoracic and Cardiovascular Surgery
Volume94
Issue number6
StatePublished - 1987

Fingerprint

Flecainide
Potassium Chloride
Ischemia
Reperfusion
Ischemic Contracture
Sodium Channels
Calcium Channels
Action Potentials
Cardiac Arrhythmias
Potassium
Krebs-Henseleit solution
Pressure
Wounds and Injuries
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Brunsting, L. A., Jessen, M. E., Ebd-Elfattah, A. S., Mask, W. K., Godwin, C. K., & Wechsler, A. S. (1987). Myocardial protective effects of the class Ic antiarrhythmic agent flecainide. Journal of Thoracic and Cardiovascular Surgery, 94(6), 904-910.

Myocardial protective effects of the class Ic antiarrhythmic agent flecainide. / Brunsting, L. A.; Jessen, Michael E; Ebd-Elfattah, A. S.; Mask, W. K.; Godwin, C. K.; Wechsler, A. S.

In: Journal of Thoracic and Cardiovascular Surgery, Vol. 94, No. 6, 1987, p. 904-910.

Research output: Contribution to journalArticle

Brunsting, LA, Jessen, ME, Ebd-Elfattah, AS, Mask, WK, Godwin, CK & Wechsler, AS 1987, 'Myocardial protective effects of the class Ic antiarrhythmic agent flecainide', Journal of Thoracic and Cardiovascular Surgery, vol. 94, no. 6, pp. 904-910.
Brunsting, L. A. ; Jessen, Michael E ; Ebd-Elfattah, A. S. ; Mask, W. K. ; Godwin, C. K. ; Wechsler, A. S. / Myocardial protective effects of the class Ic antiarrhythmic agent flecainide. In: Journal of Thoracic and Cardiovascular Surgery. 1987 ; Vol. 94, No. 6. pp. 904-910.
@article{4a45790cb5e74e6a93b2eb8d5bb6ffbb,
title = "Myocardial protective effects of the class Ic antiarrhythmic agent flecainide",
abstract = "The class Ic antiarrhythmic agent flecainide has recently become available in this country for management of ventricular arrhythmias. The pharmacologic and electrophysiologic features of this class of drug - marked sodium channel blockade producing inhibition of phase 0 of the myocardial action potential, moderate blockade of slow inward (calcium) channels, and general lack of systemic toxicity - suggest that these agents may exert significant myocardial protective effects. This hypothesis was tested in isolated, perfused rat hearts subjected to 30 minutes of global normothermic ischemia followed by 30 minutes of reperfusion after pretreatment with (1) Krebs-Henseleit buffer (n = 7); (2) Krebs-Henseleit buffer with potassium adjusted to 20.9 mmol/L with potassium chloride (n = 10); and (3) Krebs-Henseleit buffer plus flecainide acetate 50 mg/L (0.12 mmol/L) (n = 11). Severity of ischemic injury was assessed by time to ischemic contracture: 9.9 ± 1.3 (Krebs-Henseleit buffer), 18.4 ± 1.1 (potassium chloride), and 25.4 ± 1.0 (flecainide) minutes (mean ± standard error of the mean) (p < 0.05 among all groups). Functional recovery after ischemia and reperfusion was measured by developed pressure (expressed as percent of preischemic control): 19.6 ± 5.4 (Krebs-Henseleit buffer), 70.8 ± 3.2 (potassium chloride), and 67.3 ± 2.7 (flecainide). These results suggest that class Ic agents afford significant myocardial protection from global normothermic ischemia.",
author = "Brunsting, {L. A.} and Jessen, {Michael E} and Ebd-Elfattah, {A. S.} and Mask, {W. K.} and Godwin, {C. K.} and Wechsler, {A. S.}",
year = "1987",
language = "English (US)",
volume = "94",
pages = "904--910",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Myocardial protective effects of the class Ic antiarrhythmic agent flecainide

AU - Brunsting, L. A.

AU - Jessen, Michael E

AU - Ebd-Elfattah, A. S.

AU - Mask, W. K.

AU - Godwin, C. K.

AU - Wechsler, A. S.

PY - 1987

Y1 - 1987

N2 - The class Ic antiarrhythmic agent flecainide has recently become available in this country for management of ventricular arrhythmias. The pharmacologic and electrophysiologic features of this class of drug - marked sodium channel blockade producing inhibition of phase 0 of the myocardial action potential, moderate blockade of slow inward (calcium) channels, and general lack of systemic toxicity - suggest that these agents may exert significant myocardial protective effects. This hypothesis was tested in isolated, perfused rat hearts subjected to 30 minutes of global normothermic ischemia followed by 30 minutes of reperfusion after pretreatment with (1) Krebs-Henseleit buffer (n = 7); (2) Krebs-Henseleit buffer with potassium adjusted to 20.9 mmol/L with potassium chloride (n = 10); and (3) Krebs-Henseleit buffer plus flecainide acetate 50 mg/L (0.12 mmol/L) (n = 11). Severity of ischemic injury was assessed by time to ischemic contracture: 9.9 ± 1.3 (Krebs-Henseleit buffer), 18.4 ± 1.1 (potassium chloride), and 25.4 ± 1.0 (flecainide) minutes (mean ± standard error of the mean) (p < 0.05 among all groups). Functional recovery after ischemia and reperfusion was measured by developed pressure (expressed as percent of preischemic control): 19.6 ± 5.4 (Krebs-Henseleit buffer), 70.8 ± 3.2 (potassium chloride), and 67.3 ± 2.7 (flecainide). These results suggest that class Ic agents afford significant myocardial protection from global normothermic ischemia.

AB - The class Ic antiarrhythmic agent flecainide has recently become available in this country for management of ventricular arrhythmias. The pharmacologic and electrophysiologic features of this class of drug - marked sodium channel blockade producing inhibition of phase 0 of the myocardial action potential, moderate blockade of slow inward (calcium) channels, and general lack of systemic toxicity - suggest that these agents may exert significant myocardial protective effects. This hypothesis was tested in isolated, perfused rat hearts subjected to 30 minutes of global normothermic ischemia followed by 30 minutes of reperfusion after pretreatment with (1) Krebs-Henseleit buffer (n = 7); (2) Krebs-Henseleit buffer with potassium adjusted to 20.9 mmol/L with potassium chloride (n = 10); and (3) Krebs-Henseleit buffer plus flecainide acetate 50 mg/L (0.12 mmol/L) (n = 11). Severity of ischemic injury was assessed by time to ischemic contracture: 9.9 ± 1.3 (Krebs-Henseleit buffer), 18.4 ± 1.1 (potassium chloride), and 25.4 ± 1.0 (flecainide) minutes (mean ± standard error of the mean) (p < 0.05 among all groups). Functional recovery after ischemia and reperfusion was measured by developed pressure (expressed as percent of preischemic control): 19.6 ± 5.4 (Krebs-Henseleit buffer), 70.8 ± 3.2 (potassium chloride), and 67.3 ± 2.7 (flecainide). These results suggest that class Ic agents afford significant myocardial protection from global normothermic ischemia.

UR - http://www.scopus.com/inward/record.url?scp=0023571412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023571412&partnerID=8YFLogxK

M3 - Article

VL - 94

SP - 904

EP - 910

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

IS - 6

ER -